Navigation Links
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Date:6/8/2009

EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Frank Baldino, Jr., Ph.D. to its board of directors.

Dr. Baldino brings several decades of pharmaceutical and health care industry experience and leadership to ViroPharma. He is the chief executive officer and chairman of the board of directors of Cephalon Inc., an international biopharmaceutical company in Chester County, Pennsylvania. Dr. Baldino founded Cephalon in 1987 and has served as chief executive officer and director since its inception.

Prior to joining Cephalon, he served as senior research biologist in the medical products department at E.I. duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He has authored more than 100 publications in peer-reviewed journals such as Nature, Journal of Neuroscience Research, and Brain Research. Dr. Baldino received his Ph.D. in pharmacology from Temple University.

Dr. Baldino previously served as a member of ViroPharma's board of directors from 1996 to 2006.

"We are extremely pleased to welcome Frank Baldino, one of the most successful biopharmaceutical entrepreneurs, back to our board of directors," commented Vincent Milano, president and chief executive officer of ViroPharma. "For over a decade, Frank was an extraordinarily valuable member of our board, and we benefited significantly from his guidance and his experience. He brings to ViroPharma a wealth of experience in virtually any issue that a growing pharmaceutical company might encounter, and we are thrilled to welcome him back to our board."

"I am excited to have the opportunity to serve again on the board of directors of ViroPharma; I am proud of the success that the company has achieved and look forward to helping guide the company to its next level of growth and achievement," commented Dr. Baldino.

Dr. Baldino chairs the Executive Council of the Harvard Division of Sleep Medicine and is a member of the Board of Trustees at Temple University and The Franklin (formerly known as The Franklin Institute). In addition, he serves as a member of the Board of Directors for the Greater Philadelphia Chamber of Commerce, the Eastern Technology Council, BioAdvance Biotechnology Greenhouse Corp., Quaker BioVentures, L.P., and Pennsylvania BIO. Dr. Baldino is also a member of the Board of Directors for NicOx, S.A., and Acusphere, Inc.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
2. ViroPharma to Present at Two May Healthcare Conferences
3. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
4. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
5. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
6. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
7. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. ViroPharma Provides Update on Vancocin(R)
9. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
10. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
11. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company ... outserts. As a means of expanding capabilities Flottman has added a G&K ... individually code professional inserts (PIs) and patient package inserts (PPIs) that will marry ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund announced Thursday ... recommending the film Whispering Spirits and its discussion guide for use by ... education tool in the war against teen drug abuse. NCADD is the oldest ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill ... of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It ... could be set up in a matter of minutes, or even seconds. The SAFETY ...
(Date:12/9/2016)... Lee, NJ (PRWEB) , ... December 09, 2016 ... ... 2016 Founders Ball at The Pierre Hotel in New York, NY, on December ... friends, benefactors, dignitaries and physicians attended the annual event, which raised over $1 ...
(Date:12/9/2016)... ... , ... "I had a terrible time trying to get my grandson to ... the nebulizer had a more child-friendly design, then children would be more likely to ... NEBY to avoid the need to deliver medication via a nebulizer mask. The design ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
(Date:12/8/2016)... 8, 2016 Bodycad announced it has ... the accuracy, reproducibility and speed for 3D constructs ... small bone orthopaedic applications. These patents are critical ... orthopaedic restorations based on each patient,s distinct anatomy. ... company harnesses the world,s first suite of orthopaedic ...
(Date:12/8/2016)... Dec. 8, 2016  A new study by a ... use of opioid therapy to treat chronic pain is ... of more harmful consequences, including death. Palliative ... Zankhana Mehta , M.D., authored the study which ... opioid therapy. The study was published in the December ...
Breaking Medicine Technology: